Eledon Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELDN research report →
Companyeledon.com
Eledon Pharmaceuticals, Inc. , clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
- CEO
- David-Alexandre C. Gros
- IPO
- 2014
- Employees
- 31
- HQ
- Irvine, CA, US
Price Chart
Valuation
- Market Cap
- $230.21M
- P/E
- -5.52
- P/S
- 0.00
- P/B
- 4.30
- EV/EBITDA
- -2.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -96.80%
- ROIC
- -64.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-45,617,000 · -26.07%
- EPS
- $-0.56 · 25.33%
- Op Income
- $-83,251,000
- FCF YoY
- -31.88%
Performance & Tape
- 52W High
- $4.60
- 52W Low
- $1.35
- 50D MA
- $3.34
- 200D MA
- $2.62
- Beta
- 0.95
- Avg Volume
- 1.49M
Get TickerSpark's AI analysis on ELDN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 10, 26 | McBride John S. | other | 3,430 |
| Jan 10, 26 | McBride John S. | other | 3,430 |
| Jan 10, 26 | Hillson Jan | other | 3,430 |
| Jan 10, 26 | Hillson Jan | other | 3,430 |
| Jan 10, 26 | Kirk Allan | other | 3,430 |
| Jan 10, 26 | Kirk Allan | other | 3,430 |
| Jan 10, 26 | Katkin Keith | other | 8,575 |
| Jan 10, 26 | Katkin Keith | other | 8,575 |
| Jan 10, 26 | Lee June | other | 3,430 |
| Jan 10, 26 | Lee June | other | 3,430 |
Our ELDN Coverage
We haven't published any research on ELDN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELDN Report →